Drug Profile
Research programme: hepatitis C therapeutics - Innoviva
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Theravance
- Developer Innoviva
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Hepatitis-C in USA
- 01 Oct 2011 Early research in Hepatitis C in USA (unspecified route)